Class of 2025 Fellowship Directors
Jamie Adams, MD
University of Rochester Rochester, New York
Mark F. Lew, MD
University of Southern California Keck School of Medicine Los Angeles, California
Xenos Mason, MD
University of Southern California Keck School of Medicine Los Angeles, California
Jamie Adams is an associate professor of neurology, chief of the Movement Disorders Division, associate director of the Center for Health and Technology, and director of the Movement Disorders Fellowship at the University of Rochester in Rochester, New York. Her research focuses on evaluation of digital health technologies in Parkinson’ s disease and Huntington’ s disease. Dr. Adams has also led qualitative efforts to identify the most bothersome symptoms and impacts of disease and determine the relevance of digital measures to patients’ experience. Through this work, she hopes to advance the use of digital tools to facilitate development of meaningful therapies.
Mark F. Lew joined the faculty of the Keck School of Medicine of the University of Southern California in 1991, where he is now a professor of neurology and director of the Division of Movement Disorders, as well as co-director of the Annenberg Center for Biomarkers in Parkinson’ s Disease and Other Neurodegenerative Disorders. He holds the Joseph P. Van Der Meulen, MD Chair in Parkinson’ s Disease Research in honor of Robert Pasarow. Dr. Lew received his medical degree from George Washington University. He completed his neurology residency at Los Angeles County + USC Medical Center and his fellowship in movement disorders at USC.
Xenos Mason is assistant professor of clinical neurological surgery and neurology at the Keck School of Medicine of the University of Southern California. He is a neurologist and movement disorder specialist with expertise in the use of deep brain stimulation( DBS). His research focuses on procedural therapies for movement disorders, in particular DBS. In collaboration with the USC Laboratory for Neuroimaging, Dr. Mason is studying connectomic biomarkers of DBS efficacy for dystonia and other movement disorders. He is interested in the development of novel neuroimaging and neurophysiologic biomarkers to improve the delivery of DBS therapy, and on novel treatments for musician’ s dystonia and other forms of occupational dystonia. Dr. Mason is also leading development of the multidisciplinary USC Musician’ s Neurology Clinic.
18 The Edmond J. Safra Fellowship in Movement Disorders